Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.